MPN Specialists

Find a MPN Specialist in the United States – Doctor Reviewed


Kamal Patel, MD – Carti Cancer Center



John Camoriano, MD – Mayo Clinic



Angela Fleischman, MD – UC Irvine Health
David Snyder, MD – City of Hope
Jason Gotlib, MD – Stanford University School of Medicine / Stanford Cancer Center
Michael Rosove, MD – UCLA Westwood Oncology and Hematology Clinic
Catriona Jamieson, MD – UC San Diego Moores Cancer Center
David Leibowitz, MD – Sutter Health / Palo Alto Center
Lloyd Damon, MD – UC San Francisco Health



Nikolai Podoltsev, MD – Yale Cancer Center/Smilow Cancer Hospital



Brandon McMahon, MD – UC Health University of Colorado Cancer Center
Daniel Pollyea, MD – UC Health University of Colorado Cancer Center



Candido Rivera, MD – Mayo Clinic, Jacksonville
Rami Komrokji, MD – Moffitt Cancer Center
Kendra Sweet, MD – Moffitt Cancer Center
Andrew Kuykendall, MD – Moffitt Cancer Center
Chieh-Lin Fu, MD – Cleveland Clinic Florida – Weston



Elliott Winton, MD – Emory Winship Cancer Institute
Vamsi Kota, MD – Emory Winship Cancer Institute
Rebecca Klisovic, MD – Emory Winship Cancer Institute



Olatoyosi Odenike, MD – University of Chicago Comprehensive Cancer Center
Jamile Shammo, MD – Rush University Medical Center
Brady Stein, MD – Northwestern Medicine Center for Bleeding and Clotting Disorders



Larry Cripe, MD – Indiana University Health



Abdulraheem Yacoub, MD – University of Kansas Medical Center



Alison Moliterno, MD – Johns Hopkins Medicine
Jerry Spivak, MD – Johns Hopkins Medicine
Evan Braunstein, MD – Johns Hopkins Medicine
Carole Miller, MD – St. Agnes Hospital & University of Maryland Medical Center
Maria Baer, MD – University of Maryland, School of Medicine



David Steensma, MD – Dana-Farber Cancer Institute
Daniel DeAngelo, MD – Dana-Farber Cancer Institute
Martha Wadleigh, MD – Dana-Farber Cancer Institute
Eric S. Winer, MD – Dana-Farber Cancer Institute
Richard Stone, MD – Dana-Farber Cancer Institute
Jacqueline Garcia, MD – Dana-Farber Cancer Institute
Marlise Luskin, MD – Dana-Farber Cancer Institute
Gabriela Hobbs, MD – Massachusetts General Hospital Cancer Center
Jonathan Gerber, MD – University of Massachusetts Medical School



Moshe Talpaz, MD – University of Michigan Comprehensive Cancer Center
Kristen Marie Pettit, MD – University of Michigan, Michigan Medicine Bone Marrow Transplant & Leukemia



Ayalew Tefferi, MD – Mayo Clinic Rochester
Aref Al-Kali, MD – Mayo Clinic Rochester
C. Christopher Hook, MD – Mayo Clinic Rochester
Animesh Pardanani, MD – Mayo Clinic Rochester
Alexandra Wolanskyj-Spinner, MD – Mayo Clinic Rochester



Stephen T. Oh, MD – Siteman Cancer Center at Barnes-Jewish Hospital, Washington University School of Medicine


New York

Raajit Rampal, MD – Memorial Sloan Kettering Cancer Center
Michael Mauro, MD – Memorial Sloan Kettering Cancer Center
Martin Tallman, MD – Memorial Sloan Kettering Cancer Center
John Mascarenhas, MD – Mount Sinai Cancer Center, Ruttenberg Treatment Center
Ronald Hoffman, MD – Mount Sinai Cancer Center, Ruttenberg Treatment Center
Mark Heaney, MD – Columbia University Medical Center
Richard T. Silver, MD (retired) – NY Presbyterian-Weill Cornell Medical Center
Ellen Ritchie, MD – NY Presbyterian-Weill Cornell Medical Center
Marina Kremyanskaya, MD – NY Presbyterian-Weill Cornell Medical Center
Ghaith Abu-Zeinah, MD – Weill Cornell Medical Center
Michael Samuel, MD – Weill Cornell Medicine
Andrew Schafer, MD – Weill Cornell Medicine
Gail Roboz, MD – Weill Cornell Medicine
Joseph Scandura, MD – Weill Cornell Medicine
Pinkal Desai, MD – Weill Cornell Medicine
Nicole Kucine, MD – Weill Cornell Medicine
Sangmin Lee, MD – Weill Cornell Medicine
Michael Samuel, MD – Weill Cornell Medicine
Eunice Wang, MD – Roswell Park Comprehensive Cancer Center


North Carolina

Michael Grunwald, MD – Levine Cancer Institute, Carolinas Healthcare
Murat O. Arcasoy, MD – Duke Hematology Clinic
Lindsay Rein, MD – Duke Cancer Center
Harry Erba, MD – Duke Cancer Center
Brandi Reeves, MD – UNC Hospital
Dmitriy Berenzon, MD – Wake Forest Baptist Health



Aaron T. Gerds, MD – Cleveland Clinic Taussig Cancer Institute



Kim-Hien Dao, MD – Oregon Health & Science University



Elizabeth Hexner, MD – Penn Medicine
James Rossetti, MD – Hillman Cancer Center
Salman Fazal, MD – Allegheny Health Network


South Carolina

Suzanne Fanning, MD – GHS Cancer Institute



Michael Savona, MD – Vanderbilt Ingram Cancer Center
Sanjay Mohan, MD – Vanderbilt Ingram Cancer Center



Prithviraj Bose, MD – MD Anderson Cancer Center
Naval G. Daver, MD – MD Anderson Cancer Center
Naveen Pemmaraju, MD – MD Anderson Cancer Center
Srdan Verstovsek, MD – MD Anderson Cancer Center
Ruben Mesa, MD – UT Health San Antonio Cancer Center
Robyn Scherber, MD – UT Health San Antonio Cancer Center



Michael Deininger, MD – Huntsman Cancer Institute at the University of Utah
Josef Prchal, MD – Huntsman Cancer Institute at the University of Utah
Tsewang Tashi, MD – Huntsman Cancer Institute at the University of Utah



Bart Scott, MD – Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center
Joachim Deeg, MD – Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center



Laura Michaelis, MD – Medical College of Wisconsin in Milwaukee


What is an MPN Specialist?

The following article has some reasonable criteria to help determine whether your doctor is an MPN specialist or an oncologist / hematologist that sees a couple of patients a year.

If your doc has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world and never published a peer reviewed research paper, he/she isn’t likely to be an MPN specialist.  Also, if their bio lists 12+ clinical interests, their focus is NOT likely on MPN’s.  4 to 6 clinical interests would be a reasonable amount to maintain a research study focus on Myeloproliferative Neoplasms.  Here several more criteria to consider.

Publisher’s Note: 

This resource was prepared by David Wallace and another patient advocate, reviewed by an MPN Specialist and published in January, 2018.  While some physicians may have advanced degrees (Phd, MS, etc.), all MD’s have been screened as specialist in Myeloproliferative Neoplasms.  “Patient derived lists” may be dangerous to your health, as many do not even understand what constitutes a specialist in MPNs It is an ongoing project that is updated on a regular basis.  If you discover a specialist that should be added, please contact me (just below the newsletter sign up form) for the update, it will be greatly appreciated by all.

error: Content is protected !